Intra-Cellular Therapies Inc [NASDAQ: ITCI] stock went on a downward path that fall over -0.04% on Tuesday, amounting to a one-week price increase of more than 0.13%.
Over the last 12 months, ITCI stock rose by 90.56%. The one-year Intra-Cellular Therapies Inc stock forecast points to a potential upside of 0.1. The average equity rating for ITCI stock is currently 2.73, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $14.05 billion, with 106.24 million shares outstanding and 104.65 million shares in the current float. Compared to the average trading volume of 3.23M shares, ITCI stock reached a trading volume of 15546541 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Intra-Cellular Therapies Inc [ITCI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ITCI shares is $132.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ITCI stock is a recommendation set at 2.73. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Intra-Cellular Therapies Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on February 24, 2025. While these analysts kept the previous recommendation, Canaccord Genuity raised their target price from $119 to $132. The new note on the price target was released on January 31, 2025, representing the official price target for Intra-Cellular Therapies Inc stock. Previously, the target price had yet another raise from $68 to $92, while Piper Sandler kept a Overweight rating on ITCI stock.
The Average True Range (ATR) for Intra-Cellular Therapies Inc is set at 0.35, with the Price to Sales ratio for ITCI stock in the period of the last 12 months amounting to 20.63. The Price to Book ratio for the last quarter was 12.20, with the Price to Cash per share for the same quarter was set at 9.41.
ITCI Stock Performance Analysis:
Intra-Cellular Therapies Inc [ITCI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.13. With this latest performance, ITCI shares gained by 0.45% in over the last four-week period, additionally plugging by 79.90% over the last 6 months – not to mention a rise of 90.56% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ITCI stock in for the last two-week period is set at 84.55, with the RSI for the last a single of trading hit 84.30, and the three-weeks RSI is set at 82.75 for Intra-Cellular Therapies Inc [ITCI]. The present Moving Average for the last 50 days of trading for this stock 129.31, while it was recorded at 131.81 for the last single week of trading, and 92.35 for the last 200 days.
Insight into Intra-Cellular Therapies Inc Fundamentals:
Intra-Cellular Therapies Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.23 and a Current Ratio set at 6.36.
Intra-Cellular Therapies Inc [ITCI] Institutonal Ownership Details
There are presently around $96.65%, or 99.11%% of ITCI stock, in the hands of institutional investors. The top three institutional holders of ITCI stocks are: FMR LLC with ownership of 11.24 million shares, which is approximately 10.8344%. VANGUARD GROUP INC, holding 9.61 million shares of the stock with an approximate value of $$657.98 million in ITCI stocks shares; and VANGUARD GROUP INC, currently with $$432.97 million in ITCI stock with ownership which is approximately 6.0947%.
